Prospective validation study of a predictive score for operability of recurrent ovarian cancer
Standard
Prospective validation study of a predictive score for operability of recurrent ovarian cancer : the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. / Harter, Philipp; Sehouli, Jalid; Reuss, Alexander; Hasenburg, Annette; Scambia, Giovanni; Cibula, David; Mahner, Sven; Vergote, Ignace; Reinthaller, Alexander; Burges, Alexander; Hanker, Lars; Pölcher, Martin; Kurzeder, Christian; Canzler, Ulrich; Petry, Karl Ulrich; Obermair, Andreas; Petru, Edgar; Schmalfeldt, Barbara; Lorusso, Domenica; du Bois, Andreas.
In: INT J GYNECOL CANCER, Vol. 21, No. 2, 01.02.2011, p. 289-95.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prospective validation study of a predictive score for operability of recurrent ovarian cancer
T2 - the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
AU - Harter, Philipp
AU - Sehouli, Jalid
AU - Reuss, Alexander
AU - Hasenburg, Annette
AU - Scambia, Giovanni
AU - Cibula, David
AU - Mahner, Sven
AU - Vergote, Ignace
AU - Reinthaller, Alexander
AU - Burges, Alexander
AU - Hanker, Lars
AU - Pölcher, Martin
AU - Kurzeder, Christian
AU - Canzler, Ulrich
AU - Petry, Karl Ulrich
AU - Obermair, Andreas
AU - Petru, Edgar
AU - Schmalfeldt, Barbara
AU - Lorusso, Domenica
AU - du Bois, Andreas
PY - 2011/2/1
Y1 - 2011/2/1
N2 - PURPOSE: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting.METHODS: Participating centers prospectively enrolled all consecutive patients with platinum-sensitive first or second relapse. The score was applied to all patients, but centers were free to decide on therapy. All further therapies were documented, and the outcome of patients was analyzed. A 75% complete resection rate in 110 prospectively classified patients had to be achieved to confirm a positive predictive value of 2 or higher of 3 with 95% probability.RESULTS: A total of 516 patients were screened within 19 months; of these, 261 patients (51%) were classified as score positive, and 129 patients with a positive score and first relapse were operated on. The rate of complete resection was 76%, thus confirming the validity of this score regarding positive prediction of complete resectability in 2 or more of 3 patients. Complication rates were moderate including second operations in 11% and perioperative mortality in 0.8%.CONCLUSIONS: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer. It can aid in the selection of patients who might benefit from secondary cytoreductive surgery and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.
AB - PURPOSE: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting.METHODS: Participating centers prospectively enrolled all consecutive patients with platinum-sensitive first or second relapse. The score was applied to all patients, but centers were free to decide on therapy. All further therapies were documented, and the outcome of patients was analyzed. A 75% complete resection rate in 110 prospectively classified patients had to be achieved to confirm a positive predictive value of 2 or higher of 3 with 95% probability.RESULTS: A total of 516 patients were screened within 19 months; of these, 261 patients (51%) were classified as score positive, and 129 patients with a positive score and first relapse were operated on. The rate of complete resection was 76%, thus confirming the validity of this score regarding positive prediction of complete resectability in 2 or more of 3 patients. Complication rates were moderate including second operations in 11% and perioperative mortality in 0.8%.CONCLUSIONS: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer. It can aid in the selection of patients who might benefit from secondary cytoreductive surgery and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Female
KW - Health Status Indicators
KW - Humans
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Ovarian Neoplasms
KW - Prospective Studies
U2 - 10.1097/IGC.0b013e31820aaafd
DO - 10.1097/IGC.0b013e31820aaafd
M3 - SCORING: Journal article
C2 - 21270612
VL - 21
SP - 289
EP - 295
JO - INT J GYNECOL CANCER
JF - INT J GYNECOL CANCER
SN - 1048-891X
IS - 2
ER -
